Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
By C. Blank, E. Rozeman, Lorenzo F. Fanchi, K. Sikorska, B. Wiel, P. Kvistborg, O. Krijgsman, M. Braber, Daisy Philips, A. Broeks and 14 more. Nature Medicine, 2018
786 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/0077c61675cc066cfdad2338349ec3398ee17b85
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- James P. Allison
- Ton N. Schumacher
- D. Pardoll
- Padmanee Sharma
- S. Topalian
- Janis Taube
- K. Flaherty
- J. Wargo
In Oncology
- Ton N. Schumacher
- D. Pardoll
- Padmanee Sharma
- James P. Allison
- S. Topalian
- Janis Taube
- Anand Rotte
- K. Flaherty
Citations in the corpus
- Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients (2019, positive): “…node function; recent experimental data in a murine model suggests that lymph node metastases are necessary for PD-1 response 54 , and recent clinical data showing greater tumor-resident T-cell clone response to neoadjuvant compared to adjuvant immunotherapy further supports this hypothesis 55 .”
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer (2019, background): “Authors concluded that while the neoadjuvant therapy was promising, further research was needed to reduce toxicity while preserving efficacy [97].”
- Tumor-infiltrating lymphocytes in the immunotherapy era (2020, background): “The application of neoadjuvant ICB has also been successfully demonstrated in multiple tumors characterized by high mutational burden, such as melanoma and small-cell lung cancer, demonstrating impressive response rates of 78% and 45%, respectively.(209,210) In addition, neoadjuvant administration o”
- B cells and tertiary lymphoid structures promote immunotherapy response (2020, positive): “Importantly, findings of high B-cell lineage scores in responders were replicated in samples from an additional cohort of melanoma patients treated with neoadjuvant versus adjuvant checkpoint blockade (NCT02437279, OpACIN trial (n=12 R and 6 NR) 33 ( Extended Data Fig.”
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020, background): “comparing neoadjuvant versus adjuvant regimens of anti–PD-1 plus anti–CTLA-4 found a greater expansion of tumor-resident T cell clones in the peripheral blood of patients enrolled on the neoadjuvant arm (50).”